Author Archives: admin

Hunter Breast Cancer Foundation

Partnering with the Master Builders Association and Newcastle Coal Infrastructure Group, the Hunter Breast Cancer Foundation was pleased to be able to donate a second DigniCap™ scalp cooling system to Newcastle Private Hospital, making it possible to offer up to four four patients simultaneous cooling cap treatment.

Newcastle Private Hospital was the first to offer this treatment in the Hunter Region and has been able to treat over 30 patients with the cooling cap technology since March.

This donor funding was key to installing the second cooling cap system, as the cooling unit costs can be prohibitive to many small hospitals that are keen to embrace this innovative and groundbreaking technology.

Cold cap technology is currently only available in a select number of hospitals in Australia and can reduce chemotherapy induced hair loss. The device uses a small refrigerated cooling system to pump a liquid coolant through a cap, which fits snugly around the head.

A well-documented side effect of many chemotherapy drugs, hair loss, often significantly impacts the quality of life of many cancer patients. Cooling the scalp during chemotherapy means that less of the chemotherapy drug reaches the follicles and hair is less likely to fall out.

Newcastle Private Hospital aims to tailor treatment to meet the needs of individuals and their families, offering access to clinical trials, a McGrath Breast Care Nurse, a Wig Library and the most up to date treatment.

http://www.hbcf.org.au/news/hbcf-partner-to-donate-scalp-cooling-machine

photo-1

Dignicap fits for patients

DIGNICAP FITS FOR PATIENTS

CANCER patients are fighting hair loss during chemotherapy and winning thanks to a new piece of equipment on offer at Liverpool’s Sydney Southwest Private Hospital.

The DigniCap scalp cooling system is designed to help limit the amount of hair lost during chemotherapy.

Patients wear the cool cap, which makes the small blood vessels around the hair follicles contract and smaller amounts of chemotherapy reach the hair cells resulting in less hairs falling out.

Nurse Unit managers Davita Kumar and Julie Cohen have seen three patients benefit already since the new technology arrived in May.

Click here to read the full story

 

 

 

SentiMag® Now Available in Australia and New Zealand

SentiMag® Now Available in Australia and New Zealand

21st July 2014 – CAMBRIDGE, UK – Endomagnetics is pleased to announce it has reached an agreement with Aurora BioScience as its exclusive distributor for Australia and New Zealand. This appointment significantly extends the availability of the company’s SentiMag® and Sienna+® tracer system.  Breast cancer patients in the region will now have access to new technology that optimally locates lymph nodes as part of the cancer staging procedure in Sentinel Lymph Node Biopsy (SLNB).

Current standard-of-care for SLNB requires a radioactive isotope injection, which can have limited availability in Australia and New Zealand.  The SentiMag system increases the availability of the standard-of-care and also improves workflow, putting the surgeon in control of tracer injection. The system has been used in 10 clinical studies and trials with over 1,500 patients across 12 European countries since 2012.  The first two trials have published recently, and demonstrated clinical equivalence to the standard-of-care.

Aurora Bioscience is exclusively responsible for the sales, marketing and distribution of the SentiMag® system in the Australian and New Zealand markets. Aurora is a leading specialist distributor of high technology medical devices across fields including oncology, blood technology, respiratory medicine and neurology. It provides a service to metropolitan and regional areas across Australia and New Zealand and around the Pacific Islands.

Mathew Stephens, Director of Sales and Business Development at Endomagnetics said: “We are delighted to be working with the team at Aurora as this appointment significantly strengthens our distribution in this key geographical market. The interest from Australian and New Zealand surgeons has been significant and we are looking forward to developments in the coming months.”

For Aurora BioScience, Darren Banks, Managing Director said: “The Endomagnetics technology is a perfect fit with our advanced, innovative range of medical devices, and the technology will significantly improve patient experience by extending availability of the SLNB technique”.

About Endomagnetics

Endomagnetics Ltd was founded to solve cancer staging and healthcare challenges through the application of advanced magnetic sensing technology and nanotechnology. Endomagnetics is developing a portfolio of medical device products based on a patented ability to detect magnetic materials in the human body with exceptional sensitivity. The technology was originally developed at University College London and the University of Houston.

The company’s first product, the SentiMag®, is an ultra sensitive hand-held probe for tracking injected Sienna+® nanoscale magnetic materials in the human body. Cambridge, UK-based Endomagnetics is in the process of delivering its technology to global markets.

For more information please visit www.endomagnetics.com.

About Aurora BioScience

Located in Sydney Australia, Aurora BioScience Pty Ltd is committed to providing advanced, high quality medical devices and healthcare products to assist medical professionals within Australia, New Zealand and the Pacific Islands healthcare markets, to contribute to the enhancement of patient’s quality of life. Areas of interest include cancer therapies, neurology, pulmonology, and haematology and blood products.

For more information, please visit www.aurorabioscience.com.au

Cold Cap Technology Comes to Newcastle

Cold Cap Technology Comes To Newcastle

Cancer patients in Newcastle will soon be offered a solution to hair loss caused by chemotherapy treatment with the introduction of cold cap technology from Thursday, 1 May 2014 at Newcastle Private Hospital.

A well-documented side effect of many chemotherapy drugs, hair loss often significantly impacts the quality of life of many cancer patients. Novocastrians will now be able to combat this side effect via cold cap technology.

This latest investment continues Newcastle Private Hospital’s commitment to increasing access to innovative and cutting edge technology.

“This acquisition enhances our existing oncology services and provides cancer patients with the most up to date treatments in modern, caring surroundings,” Newcastle Private Hospital General Manager Michael Mitchell said.

Widely used in Europe, cold cap technology is currently only available in a small number of hospitals in Australia and can reduce chemotherapy-induced alopecia.

“For many patients, undergoing chemotherapy is a very difficult time and a sudden change in appearance can be a visual reminder of the disease and treatment,” Michael continued.

“We are thrilled to now offer advanced cold cap technology to our patients and help them through what can be a daunting and challenging experience.”

The scalp cooling Dignicap System will be available to patients undergoing chemotherapy and reduces the chance of hair loss from the head.

The device uses a small refrigerated cooling system to pump a liquid coolant through a cap, which fits snugly around the head. Cooling the scalp during chemotherapy means that less of the chemotherapy drug reaches the follicles and hair is less likely to fall out.

The system is effective with most chemotherapy drugs, with eight out of 10 users keeping their hair and feeling no need to wear a wig.

(Source: http://www.hunterheadline.com.au/business-news/cold-cap-technology-comes-to-newcastle )

New Distribution Agreement with Synapse Biomedical Announced

SYDNEY, Australia. Aurora BioScience Pty. Ltd. today announced that it has entered into an exclusive distribution agreement for Australia and New Zealand with Synapse Biomedical Inc. to provide that company’s innovative NeuRx Diaphragm Pacing System (DPS)®.

The NeuRx Diaphragm Pacing System introduces groundbreaking neurostimulation technology designed to help spinal cord injury patients and other patients with breathing problems, such as Motor Neurone Disease, decrease their dependency on mechanical ventilation – enhancing their quality of life. The NeuRx DPS® uses a minimally invasive procedure to establish a deeper and more comfortable breathing pattern.

The NeuRx DPS® consists of four (4) electrodes implanted in the diaphragm to stimulate the muscle, a fifth (5th) electrode under the skin to complete the electrical circuit, a connector holder, a cable and an external battery powered pulse generator. The pulse generator provides the timing and control of stimulus to regulate movement of the diaphragm muscle and affect respiration.

Aurora BioScience entered into an exclusive distribution agreement with Synapse Biomedical Inc. in March 2014; under the agreement Aurora Bioscience will be exclusively responsible for the sales, marketing and distribution in both the Australian and New Zealand markets.

“Every now and then, a truly innovative and important medical advancement occurs; one that has the potential to significantly improve the lives of patients. The NeuRx DPS® is exactly one of those products” said Darren Banks, Managing Director of Aurora BioScience. “This technology really is life transforming”.

Synapse Biomedical Inc. was founded in September 2002 to commercialize the NeuRx Diaphragm Pacing System (DPS)® that has been developed over a twenty-year period at Case Western Reserve University and the University Hospitals of Cleveland. The innovative research performed at these institutions has led to significant advances in the state of the art of electrical stimulation for the treatment of chronic respiratory insufficiency. This innovation allows the technology to meet clinical needs, beyond the ability of the currently available systems, in spinal cord injuries, in the diaphragm conditioning in muscular dystrophies (such as MND) and in respiratory short-term intensive care setting.

“We are extremely excited to be partnering with such an innovative company as Synapse Biomedical and believe the NeuRx DPS® system can have a significant impact of patient’s lives here in Australia and New Zealand. We are expecting to be involved in our first procedures in April 2014 after finishing meetings and discussions with both clinical opinion leaders and Patient Advocacy groups”. stated Mr. Banks.

About Aurora BioScience Pty Ltd

Located in Sydney Australia, Aurora BioScience is committed to providing advanced, high quality medical devices and healthcare products to assist medical professionals within Australia, New Zealand and the Pacific Islands healthcare markets, to contribute to the enhancement of patient’s quality of life. Our areas of interest include cancer therapies, neurology, pulmonology, and haematology and blood products.

For more information, please visit www.aurorabioscience.com.au

About Synapse Biomedical Inc.

Our culture is best described by its people: smart, driven, energetic and committed to improve the lives of individuals with neurological impairment, such as spinal cord injury, motor neurone disease and others.

At Synapse Biomedical, our mission is to commercialize our life transforming neurostimulation technology platform used to treat people with respiratory insufficiency.

www.synapsebiomedical.com

Fenwal – Change of Distributor

Fresenius Kabi and Aurora BioScience change of supply arrangements for the Fenwal portfolio in Australia and New Zealand 

Fresenius Kabi Australia Pty Limited is pleased to advise in November 2012, Fenwal Inc. was acquired and became a Fresenius Kabi company. This represents an exciting new era for Fresenius Kabi and we look forward to sharing with you the added resources and enhanced capabilities that this new partnership brings.

Since 2008, Aurora BioScience Pty Ltd has been the local distributor of the Fenwal portfolio in Australia and New Zealand. Fresenius Kabi Australia Pty Limited has taken on the supply of the Fenwal product portfolio locally. Both companies will continue to work closely together during the transition of this portfolio to ensure there is no interruption to supply throughout the transition.

Fresenius Kabi Australia Customer Service: 1300 732 001 or Fax: 1300304 384

EMCOOLS and Aurora BioScience

Pioneering Technology – Easy and Efficient Patient Cooling

SYDNEY, Australia. Aurora BioScience Pty. Ltd. today announced that it has officially launched the EMCOOLS range of innovative cooling devices designed to improve survival rates and neurological outcome after acute ischaemic events and in various hyperthermic diseases like sepsis, heatstroke or malignant hyperthermia.

The core of these innovative products is a unique development called HypoCarbon®, which is a highly efficient cooling technology at the heart of the EMCOOLS surface cooling systems.

The reduction of a patient’s core body temperature, known as therapeutic hypothermia, increases the chances of survival and reduces the risk of neurological damage following a period of insufficient blood flow either locally (stroke / myocardial infarction) or throughout the whole body (cardiac arrest). Intact nerve cells are protected and the number of free radicals, which might damage cells after ischaemic periods, is reduced.

In addition, temperature reduction to normothermia (36.0°C – 37.5°C) increases the chances of survival and improves the neurological outcome in various hyperthermic diseases like malignant hyperthermia or in febrile stroke patients.

Aurora BioScience entered into an exclusive distribution agreement with the Austrian based manufacturer, EMCOOLS, in late 2012; under the agreement Aurora Bioscience will be exclusively responsible for the sales, marketing and distribution in both the Australian and New Zealand markets.

“The EMCOOLS range really is smart, flexible and simple.” said Darren Banks, Managing Director of Aurora BioScience. “The unique technology within the temperature pads provides an effective and efficient outcome. Therapeutic hypothermia is now an established therapy that greatly contributes to improved survival with improved neurological outcome.”

Many peak bodies around the world (European Resuscitation Council, American Heart Association, ILCOR) all recommend therapeutic hypothermia after out of hospital cardiac arrest or stroke.

“We are excited to be partnering with such an innovative company as EMCOOLS and believe the EMCOOLS system can assist clinicians provide improved patient outcomes. We are currently in negotiations with a world renown specialist to undertake the first evaluations to be undertaken in Australia later this year with many hospitals extremely keen to evaluate the product” stated Mr. Banks.

About Aurora BioScience Pty Ltd

Located in Sydney Australia, Aurora BioScience is committed to providing advanced, high quality medical devices and healthcare products to assist medical professionals within Australia, New Zealand and the Pacific Islands healthcare markets, to contribute to the enhancement of patient’s quality of life. Our areas of interest include cancer therapies, neurology, pulmonology, haematology and blood products.

For more information, please visit www.aurorabioscience.com.au

About EMCOOLS

Since its founding almost 10 years ago EMCOOLS Medical Cooling Systems AG has established themselves as a leading European company in the field of therapeutic patient cooling. Our passion for innovation leads to new products and solutions which give our customers more opportunities, currently in more than 40 countries worldwide.

www.emcools.com

 

 

 

 

 

 

 

New Website Launched for dermaPACE

A new website that provides access to a wide array of information concerning the dermaPACE device was launch today to coincide with the Australasian Podiatry Conference in Sydney 2nd to 5th June 2013.

www.dermapace.com.au provides an overview of this ground breaking technology along with access to clinical papers and other useful information.

Make sure you visit Aurora BioScience at the Podiatry Conference (Stand 111) to see the device in action.

Aurora BioScience Pty. Ltd. today announced that it has launched the dermaPACE wound healing system

By Aurora BioScience Dated: Mar 18th 2013

dermaPACE – Advanced Wound Healing Technology.

SYDNEY, Australia. Aurora BioScience Pty. Ltd. today announced that it has launched the dermaPACE wound healing system.

The dermaPACE system from Sanuwave Health, utilises Pulsed Acoustic Cellular Expression (PACE®) technology, or high-energy acoustic pressure waves in the shock wave spectrum to produce compressive and tensile stresses on cells and tissue structures to elicit a series of biological responses. PACE® treatment results in an increase in perfusion and arteriogenesis, biofilm disruption, a pro-inflammatory response, cytokine and chemokine effects, growth factor up-regulation, angiogenesis (new blood vessel formation) and the subsequent regeneration of tissue such as skin, musculoskeletal and vascular structures.

Aurora BioScience entered into an exclusive distribution agreement with Sanuwave Health in 2012 and received Therapeutic Goods Administration (TGA) approval in March 2013. Under the agreement Aurora Bioscience will be exclusively responsible for the sales, marketing and distribution in both the Australian and New Zealand markets.

“The dermaPACE system really is an exciting new development for the treatment of wounds, especially chronic, difficult to treat wounds.” said Darren Banks, Managing Director of Aurora BioScience. “ Both Sanuwave and Aurora believe in the potential for PACE® technology to positively impact patients whose lives suffer from debilitating wounds and injuries.”

The dermaPACE system is designed to provide extracorporeal shock wave therapy (ESWT) intended to treat acute and chronic conditions of the skin and subcutaneous soft tissues (eg, arterial, venous, diabetic or pressure ulcers, burns, postoperative or traumatic wounds).

“We are excited to be partnering with such an innovative company as Sanuwave Health and believe that the dermaPACE device can assist healthcare professionals provide improved patient outcomes. We are expecting the first procedures to be undertaken in Australia in late March with many hospitals and clinics extremely keen to evaluate the product” stated Mr. Banks.

About Aurora BioScience Pty Ltd

Located in Sydney Australia, Aurora BioScience is committed to providing advanced, high quality medical devices and healthcare products to assist medical professionals within Australia, New Zealand and the Pacific Islands healthcare markets, to contribute to the enhancement of patient’s quality of life. Our areas of interest include wound healing, cancer therapies, neurology, pulmonology, haematology and blood products. For more information, please visit www.aurorabioscience.com.au

About Sanuwave

SANUWAVE Health, Inc. is an emerging leader in the development and commercialization of noninvasive, biological response activating devices in the regenerative medicine area for the repair and regeneration of tissue, musculoskeletal and vascular structures. SANUWAVE’s portfolio of products and product candidates activate biologic signaling and angiogenic responses, including revascularization and microcirculatory improvement, helping restore the body’s normal healing processes and regeneration. SANUWAVE is applying its Pulsed Acoustic Cellular Expression (PACE) technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Headquartered in Alpharetta, GA, SANUWAVE designs, manufactures, markets, and services its industry leading products worldwide.

http://sanuwave.com/international/dermapace/